WO2019091397A1 - Utilisation d'azido phlorizine dans la préparation d'un médicament destiné au traitement de la stéatose hépatique non alcoolique - Google Patents

Utilisation d'azido phlorizine dans la préparation d'un médicament destiné au traitement de la stéatose hépatique non alcoolique Download PDF

Info

Publication number
WO2019091397A1
WO2019091397A1 PCT/CN2018/114329 CN2018114329W WO2019091397A1 WO 2019091397 A1 WO2019091397 A1 WO 2019091397A1 CN 2018114329 W CN2018114329 W CN 2018114329W WO 2019091397 A1 WO2019091397 A1 WO 2019091397A1
Authority
WO
WIPO (PCT)
Prior art keywords
ggpps
liver
fatty liver
medicament
preparation
Prior art date
Application number
PCT/CN2018/114329
Other languages
English (en)
Chinese (zh)
Inventor
薛斌
李朝军
齐雅玲
Original Assignee
南京大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 南京大学 filed Critical 南京大学
Publication of WO2019091397A1 publication Critical patent/WO2019091397A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Definitions

  • the invention belongs to the field of medicine, and particularly relates to the use of azidoin for the preparation of a medicament for treating non-alcoholic fatty liver.
  • Azidopidin can reduce lipid accumulation in the liver and has a significant effect on the treatment of nonalcoholic fatty liver.
  • Nonalcoholic fatty liver disease refers to excessive deposition of fat in liver cells caused by factors other than alcohol.
  • the development process generally includes simple fatty degeneration of the liver, steatohepatitis, liver fibrosis, etc., and severe cirrhosis. , liver failure and even liver cancer.
  • the prevalence of the disease continues to increase globally, in parallel with the increase in obesity, and is increasingly becoming a serious public health problem.
  • Nonalcoholic fatty liver disease is the result of multiple factors such as genetic-environment-metabolism-stress, and is closely related to metabolic syndrome such as insulin resistance, hyperglycemia and hyperlipidemia.
  • metabolic syndrome such as insulin resistance, hyperglycemia and hyperlipidemia.
  • many international guidelines on early nonalcoholic fatty liver disease treatment strategies focus on lifestyle changes, as well as prevention of accompanying metabolic and cardiovascular complications.
  • drug treatment for the liver must be used to prevent the progression of liver disease and reduce or prevent liver cirrhosis and its complications.
  • the mevalonate pathway (MVA pathway) is an important pathway in the cellular metabolic pathway.
  • acetyl-CoA is first produced by 3-hydroxy-3-methylglutaryl coenzyme A synthetase to form 3-hydroxy-3-methylglutaryl coenzyme A, followed by 3- Mevalonate is produced by the action of hydroxy-3-methylglutaryl coenzyme A reductase.
  • the product of the pathway can be regarded as an activated isoprene unit, which is a synthetic precursor of biomolecules such as steroids and terpenoids.
  • metabolic intermediates such as farnesyl diphosphate (FPP) and geranylgeranyl diphosphate (GGPP) are also important substrates for the synthesis of cholesterol, terpenoids and terpenoids. , occupy an important position in a variety of physiological processes.
  • the key branching enzyme in the mevalonate pathway Geranylgeranyl Diphosphate Synthase (GGPPS), catalyzes the formation of geranylgeranyl pyrophosphate by farnesyl pyrophosphate, which mediates the protein isoprenic acid.
  • GGPPS Geranylgeranyl Diphosphate Synthase
  • the balance of olefination affects the development of non-alcoholic fatty liver and type 2 diabetes by affecting the regulation of protein prenylation in the liver.
  • GGPPS is involved in the formation of insulin resistance under high insulin status by regulating the relative activation of MAPK/PI3K/AKT signaling pathway; GGPPS-regulated protein prenylation modification promotes fatty acid-induced muscle insulin resistance; GGPPS
  • the proportion of FPP/GGPP regulated in vivo is involved in the regulation of lipid metabolism in the liver.
  • GGPPS can participate in the regulation of obesity-induced liver fat degeneration by regulating the proportion of FPP/GGPP in vivo. Therefore, knocking out GGPPS gene can effectively alleviate the formation of nonalcoholic fatty liver, so it is proposed to use GGPPS. Screening for effective treatment of nonalcoholic fatty liver for the target.
  • Azidopidin is an analog of phenolic compounds found in apples, apple bark and leaves. Phlorizin is extracted from apple, apple bark and leaves, and is a phenolic substance in apple trees. 4-Azidophlorizin (4-Az) is a derivative of phloridin with the following chemical structure:
  • Azidoin has been reported as a kidney-expressed sodium-dependent glucose transporter 2 (SGLT-2) inhibitor, which inhibits renal reabsorption of glucose, but no studies have shown Whether 4-Az has the effect of promoting degradation of the GGPPS protein.
  • Azidotin can directly target GGPPS, trigger GGPPS degradation through the ubiquitination-proteasome pathway, thereby blocking the transmission of multiple signaling pathways involved in the guanosine triphosphate family (GTPase), and inhibiting the liver.
  • GTPase guanosine triphosphate family
  • an object of the present invention is to provide a use of azidopidin in the field of medicine, and in particular to its use in the preparation of a medicament for treating nonalcoholic fatty liver.
  • the inventors established a non-alcoholic fatty liver mouse model by high-fat induction, and observed the effects of azidoin on the body weight, liver tissue lipid metabolism and accumulation, and liver in nonalcoholic fatty liver mice. The impact of the function.
  • the medicament of the present invention may comprise dimethyl sulfoxide, azidoin and a pharmaceutically acceptable carrier, which may be administered intraperitoneally, and the dose may be 1-10 mg. /kg.
  • the administration mode of the drug may also be subcutaneous, intradermal, intraarterial, intravenous, intramuscular, intraarticular, intrasynovial, intrasternal, intrathecal, intralesional, intracranial injection or infusion, oral, topical, rectal , nasal, buccal, vaginal, sublingual, intradermal, mucosal, tracheal, urethra administration, by inhalation aerosol, implant accumulation and acupuncture.
  • the examples of the present invention examined changes in body weight and liver weight and liver lipid accumulation in mice injected with non-alcoholic fatty liver after azigal glucosinolate injection.
  • the results show that the present invention has the following beneficial effects:
  • the azidoin glucoside of the present invention can effectively reduce lipid accumulation and fatty degeneration in the liver, and can lower the levels of alanine aminotransferase and aspartate aminotransferase in blood, and has activity for protecting liver function, and thus can be used for
  • the preparation of drugs for treating nonalcoholic fatty liver has potential and good application prospects in the field of nonalcoholic fatty liver treatment.
  • the present invention not only provides a high level of targeted drugs for the development of new drugs for nonalcoholic fatty liver, but also provides a new idea for individualized diagnosis and precise medical treatment of metabolic diseases caused by protein isoprene imbalance. .
  • the inventors compared the effects of azidoin and phloridin on lipid metabolism in hepatocytes at the cellular level. effect. The results showed that the effect of azidoin on hepatic lipid metabolism was far more significant than phloridin.
  • Figure 1 shows the expression levels of GGPPS under different conditions.
  • both A and B maps show that the expression of GGPPS is decreased in TSC2-null cells under 4-Az treatment;
  • C is 4-Az causing reversal of RhoA protein prenylation;
  • Figure D is 4-Az does not cause GGPPS Changes in transcript levels;
  • E map shows that the proteasome inhibitor MG132 is able to reverse the decrease in GGPPS expression caused by 4-Az;
  • F is a graph showing that the autophagosome-lysosomal inhibitor CQ does not reverse the decrease in GGPPS expression caused by 4-Az.
  • Figure 2 shows the inhibition of GGPPS by 4-Az.
  • Panel A shows that 4-Az promotes GGPPS ubiquitination accumulation, thereby causing degradation.
  • Panels B to E are micro thermophoresis screening systems showing binding of 4-Az to GGPPS recombinant protein.
  • Figure 3 is a graph showing changes in body weight and major lipid metabolism tissue weight in nonalcoholic fatty liver mice after continuous administration of different concentrations of azidoin for 14 days.
  • the graph A shows the change in body weight of the mouse within 14 days (administered and monitored every other day);
  • the graph B shows the ratio of liver weight to body weight of the mouse after the last administration on the 14th day;
  • Fig. 4 is a graph showing changes in lipid content in the liver of mice with nonalcoholic fatty liver after 14 days of continuous administration of different concentrations of azidoin.
  • the picture A is the CT scan of the liver of the mouse after the last administration on the 14th day
  • the picture B is the liver tissue density of the mouse obtained by the 40keV tube voltage scan after the last administration on the 14th day
  • Mouse liver lipid content after the last dose of 14 days.
  • Fig. 5 is a photomicrograph of liver paraffin sections and HE staining of nonalcoholic fatty liver mice after continuous administration of different concentrations of azidoin for 14 days.
  • the A picture is the light micrograph of the liver of the mouse after the last administration on the 14th day
  • the B picture is the liver triglyceride content of the mouse after the last administration on the 14th day.
  • Fig. 6 is a graph showing changes in the contents of alanine aminotransferase and aspartate aminotransferase in the blood of mice with nonalcoholic fatty liver after 14 days of continuous administration of different concentrations of azidoin.
  • Figure A shows the content of alanine aminotransferase in the blood of mice after the last administration on the 14th day
  • B is the content of aspartate aminotransferase in the blood of mice after the last administration on the 14th day.
  • MATERIALS The recombinant plasmid pET28a and its expression vector were constructed by the company. The target gene was inserted between the NcoI and BamI restriction sites, and cloned into the GGPPS-EGFP-His gene to facilitate the green fluorescence excitation of the exogenous protein GGPPS. E. coli BL21 was purchased and stored by the company. TSC2-null cells are a gift from the American laboratory. A plasmid extraction kit, a gel recovery kit, and a PCR product purification kit were purchased from Axygen Corporation.
  • Type IV collagenase trypsin was purchased from Gibco. Protease inhibitors cocktail, BSA, SDS, GGPP, FPP, STA-21, etc. were purchased from Sigma. GGPPS, Ub antibody was purchased from Santa Cruz. PVDF membranes were purchased from Roche. Ni-IDA Resin, GST-Resin, chromatography column, Ni column affinity filler, purchased from Jiangsu Zibo Biotechnology Co., Ltd. The ultracentrifuge was purchased from Beckman. The cryogenic centrifuge was purchased from Kubota. The Western Blot system was purchased from Tianneng.
  • TSC2-null was grown in DMEM containing 10% calf serum, 90% high glucose DMEM + 10% FBS medium, 0.25% trypsin, PBS, DMSO. Place in a 5% CO2, 95% air, 37 ° incubator. Pay attention to the change of PH value in the medium, change the liquid regularly, and repeat the subculture or cryopreservation when the cell density reaches 70%-80%.
  • Transfection was carried out by culturing TSC2-null cells (60 mm culture dishes) until the cell fusion rate was 60% or more. Lightly mix 10 ul of siRNA with 500 ul of OPTI medium in a sterile tube according to Invitrogen's LipofectamineTM 2000 Transfection Instructions. 10 ul of LipofectamineTM 2000 was diluted in 500 ul of OPTI medium, allowed to stand at room temperature for 5 min, and then the above two solutions were gently mixed, so that the liposome lipo was wrapped in the plasmid and incubated at room temperature for 20 min. Plasmid transfection is then performed. After 48 hours of transfection, cells were collected for sampling.
  • the culture solution was discarded, and the monolayer cells were washed twice with pre-PBS (pH 7.4), and then the cells were lysed by adding an appropriate amount of a protease-containing cell lysate, and the lysate was heated at 100 ° C for 10 minutes.
  • the cell debris was removed by centrifugation at 13,000 rpm, and the supernatant was taken and stored at -20 ° C or -70 ° C.
  • RNA extraction refers to Real time PCR
  • the culture solution is discarded.
  • the monolayer cells 35 mm dish
  • the monolayer cells were washed with PBS, 1 mL of Trizol Reagent was added, and immediately pipetted to thoroughly mix. After the cells were detached, the lysate was transferred to a centrifuge tube and allowed to stand at room temperature for 5 minutes. 0.2 mL of chloroform was added, and the mixture was thoroughly mixed, allowed to stand at room temperature for 15 minutes, and centrifuged at 4 ° C for 12,000 g for 10 minutes.
  • An electrophoresis gel was prepared and subjected to SDS-PAGE.
  • the electrophoresis time is generally 4 to 5 hours.
  • 80V pre-electrophoresis is performed, and the sample is sent to the separation gel to change the voltage to 120V.
  • Electrophoresis until the bromophenol blue has just run out can terminate the electrophoresis and transfer the film. Stacked in the order of filter paper-gel-PVDF film-filter paper, the gel is close to the negative electrode, and the film faces the positive electrode, and the bubbles between the layers are removed. Immunoblotting reactions were performed with the corresponding antibodies.
  • the first antibody dilution and reaction conditions were as follows: ⁇ -Tubulin (1:1000), GGPPS (1:200), Rap1A (1:200), RhoA (1:200) 4 °C Incubate overnight for 12-16 hours, wash the membrane 3 times with PBS for 10 min each time, incubate HRP-labeled fluorescent secondary antibody for 2 hours at room temperature, and wash the membrane 6 times with PBS for 5 min each time. After washing, it is chemiluminescence, and exposure and development are retained.
  • the BL-21 strain containing the recombinant plasmid of the target gene was cultured on a large scale, and the expressed target protein was labeled with His, the loading speed was 2 mL/min, and the penetrating sample was collected for subsequent sample preparation to determine the gel. Whether the target protein is hung on the column; after the sample is finished, use the Ni column buffer buffer buffer W to clean the non-protein bound to the Ni column, elute the buffer buffer B with Ni column, 3 mL/min, elute with the Ni column.
  • Binding the target protein observe the change of the absorption peak at 280 nm, collect the eluted protein at the sample outlet at the appropriate time, inject the collected eluted protein into the dialysis card, and place the dialysis card in PBS buffer containing 10% glycerol. After standing at 4 ° C for 12 h, 1 L of PBS (without glycerol) was prepared, and a dialysis card was placed therein, and placed at 4 ° C for 12 h. The prepared prokaryotic purified protein GGPPS-EGFP-His was partially protected from light at 4 °C for subsequent experiments, and partially frozen at -80 °C for long-term storage.
  • Microscale Thermophoresis is a fluorescent colorimetric quantitative technique that has been applied to biological analysis in recent years based on physical principles.
  • the change in molecular hydration shell, electrical or size can be monitored by measuring the change in motion of the molecule under a microtemperature gradient.
  • the interaction between multiple biomolecules, such as liposomes and ribonic acid can be quickly monitored from ions or fragments.
  • the prepared prokaryotic purified protein GGPPS-EGFP-His was used as a macromolecular ligand, and the small molecule substrate FPP of GGPPS was used as a positive detecting substance for the GGPPS binding screening model. At the same time, 4-Az was used as the compound to be detected. Prior to the test, the mixture was stirred by centrifugation (5 minutes, 13,000 rpm, 4 ° C). Tween 20 (0.01% - 0.1%) was used as a cleaning agent to remove the original polymerization. The fluorescence value of the GGPPS fusion fluorescent protein at 20% LED POWER was measured and controlled to be in the range of 200 to 1000.
  • the concentration of the fluorescent binding protein was unchanged, and the label-free binding ligand was diluted with a dilution buffer of 1:1 into 16 concentrations of the titration solution.
  • the fluorescent binding protein was incubated with the label-free binding ligand in a 1:1 ratio and loaded into a capillary tube for micro thermophoresis.
  • Example 1 Effect of 4-Az on endogenously highly expressed GGPPS protein levels.
  • TSC2-null cells were cultured to a density of 50%. At this time, the cells were changed, and blanks, drug solvent negative control (DMSO), GGPP transferase inhibitor (GGTI), GGPPS small interfering RNA were used for different treatment groups. siGGPPS), and concentration gradient of 4-Az drug (0.5 uM, 5 uM, 50 uM). After 48 h treatment, cells were harvested and protein levels were detected. It was found that the concentration of GGPPS was down-regulated as the concentration gradient increased. The TSC2-null protein was collected at 0 hours, 12 hours, 24 hours, and 48 hours, respectively, and the expression level of GGPPS was detected. It was found that the protein level of GGPPS showed a time-dependent decrease after drug treatment. The above results show that 4-Az can significantly reduce endogenous GGPPS protein levels.
  • Example 3 4-Az promotes ubiquitination degradation of GGPPS
  • the ubiquitination-proteasome inhibitor MG132 and the lysosomal-autophagosome fusion inhibitor CQ were treated respectively.
  • the two degradation pathways were destroyed, only the treatment of MG132 prevented the expression of GGPPS. decline. And as the concentration of MG132 increases, the expression of GGPPS rises.
  • the ubiquitination-proteasome inhibitor MG132 was able to reverse the decrease in GGPPS expression caused by 4-Az.
  • Embodiment 4 4-Az can directly combine the mode of action of GGPPS
  • the concentration of the GGPPS-EGFP-His fluorescent expression fusion protein obtained by the purification was kept constant, and the concentration of the FPP concentration of the GGPPS positive control substrate used for each titration was changed.
  • the thermophoretic motion without GGPPS is different from the motion of the substrate FPP which has been combined with GGPPS.
  • the fluorescence signal of GGPPS is normalized and processed at different FPP concentrations to form Kd.
  • the titrant was replaced with the naturally active small molecule to be identified, and fluorescence detection showed direct binding of 4-Az to GGPPS compared to control EGFP. It can be seen that 4-Az promotes GGPPS degradation by directly binding to GGPPS to promote the ubiquitination of GGPPS.
  • mice Four-week-old mice (C57BL/6J) were purchased from the Institute of Model Animals, Nanjing University.
  • the mouse feed was purchased from Jiangsu Synergy Bioengineering Co., Ltd.
  • High fat feed was purchased from Research Diets, New Brunswick, NJ.
  • Azidopidin is purchased from Shanghai Taosu Biochemical Co., Ltd.
  • the liver tissue triglyceride test kit was purchased from Pratt Bioengineering Co., Ltd.
  • the alanine aminotransferase and aspartate aminotransferase assay kits were purchased from KGI Biotechnology Development Co., Ltd.
  • azidopidin preparation Dissolve azid phlorizin powder in Dimethyl Sulphoxide (DMSO), dissolved in two dose groups of 1 mg/kg and 10 mg/kg. The concentration was 0.15 g/L and 1.5 g/L.
  • DMSO Dimethyl Sulphoxide
  • the placebo solution was the solvent DMSO of the azidopidin preparation.
  • liver tissue triglyceride Take about 50 mg of the right lobe of mouse liver tissue and record the exact weight.
  • the PBS was washed with water and placed in 1 ml of lysate and mechanically homogenized.
  • the lysed tissue homogenate was divided into two parts. A portion of 500 ul was placed in a 70 ° C metal bath, heated for 10 min, and centrifuged at 2,000 x rpm for 5 min. Take 1-10 ul for tissue TG kit detection. An additional 500 ul was used to detect protein concentration by the BCA method.
  • Paraffin section preparation Take the right amount of liver tissue, fix it with 4% paraformaldehyde for 24-48h, dehydrate the ethanol step by step, transparent xylene, dipped in wax, embedded in paraffin, sliced, and the thickness is 5 ⁇ m.
  • HE staining of paraffin sections The sections were immersed in xylene for 10 min and 5 min for dewaxing, respectively, and then water was added to the gradient ethanol. After 4 min of hematoxylin staining, the steamed water was slightly washed. It was blanched with 0.25% NH 3 ⁇ H 2 O for 30 s and then washed with water. After dehydration with a gradient of ethanol to 95% ethanol, 0.5% eosin was stained for 2-3 s, then dehydrated in 100% ethanol, and soaked in xylene for 2 min. Finally, the film is sealed with a neutral gum.
  • Detection of alanine aminotransferase and aspartate aminotransferase levels After anesthesia in mice, blood was taken through the orbital vein and placed at room temperature for 30 min until the serum was precipitated and centrifuged. 10 ul of serum was taken for detection of alanine aminotransferase and aspartate aminotransferase kits.
  • Example 1 Establishing a non-alcoholic fatty liver mouse model
  • Non-alcoholic fatty liver model rats were induced by food-borne induction. High-fat diets (containing 60% fat) were fed to 4-week-old mice in the "General Materials and Methods" for 8 weeks, and 8 weeks later, they were successfully induced to produce fatty liver.
  • mice in Example 1 were randomly assigned to 3 groups, 6 in each group, and were set to "4-Az 1" group, "4-Az 10" group, and control group.
  • the above three groups of mice were intraperitoneally injected with an equal volume of 1 mg/kg dose of azid phagemidin preparation, 10 mg/kg dose of azid phagemidin preparation and dimethyl sulfoxide (as a placebo). The injection was given every other day for 14 consecutive days, and the changes in body weight of the mice were simultaneously monitored.
  • the body weight, liver weight and epididymal fat of mice injected with azidopistin were significantly lower than those of the control group, indicating azide.
  • the phloridin can significantly reduce the body weight of non-alcoholic fatty liver mice.
  • each group of mice was sacrificed and the relevant physiological indexes were examined.
  • the liver tissues of each group of mice were subjected to CT scanning, and the liver tissues of each group of mice were subjected to triglyceride level detection and paraffin section HE staining according to the procedure described in "General Materials and Methods".
  • the liver tissue density of the mice injected with the azidopidin preparation was significantly higher than that of the control mice, and the lipid content was significantly lowered.
  • Panel A shows that non-alcoholic fatty liver mice administered with an azido phlorizin preparation have significant remission of hepatic macrovesicular steatosis compared with the control group, while B shows The triglyceride content was significantly reduced, indicating that azidoin can reduce the lipid-induced hepatic lipid degeneration.
  • Example 4 Effect of azidoin on the levels of alanine aminotransferase and aspartate aminotransferase in blood of mice After 14 days of continuous administration in Example 2, the levels of alanine aminotransferase and aspartate aminotransferase in the blood of mice were measured. As shown in Fig. 4, the results of A and B show that the mice injected with azidopidin preparation have significantly lower levels of alanine aminotransferase and aspartate aminotransferase in the blood compared with the control mice. Azidoin spectrase relieves hepatotoxicity caused by high-fat feeding and has activity to protect liver function.
  • Example 5 Differences in lipid metabolism in hepatocytes at the cellular level by azidoin and phloridin 1. Construction of hepatic steatosis model
  • This model is a cellular model that mimics the cellular environment of nonalcoholic fatty liver with lipid-denatured hepatocytes.
  • Primary hepatocytes from 8 week old mice were isolated and plated to approximately 80% of culture dishes.
  • the bovine serum albumin (BSA) which is a free fatty acid and a free fatty acid, was used as a negative control to stimulate the cells.
  • hepatocyte lipid degeneration model On the basis of the hepatocyte lipid degeneration model, three groups were internally set as DMSO group, 4-Az drug treatment group (10 ⁇ M, 20 ⁇ M, 50 ⁇ M) and phlorizin drug treatment group (100 ⁇ M).
  • the results of the cytology triglyceride kit showed that in the BSA group, the TG content of the cells decreased when the drug treatment concentration reached 50uM, and the triglyceride group was 4 times more than the negative control BSA group after the free fatty acid treatment. Significantly elevated, on the basis of this, it was found that the triglyceride content had been significantly decreased and the TG reduction rate was 65% under the treatment of the lowest concentration of 10 uM 4-Az.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'azido phlorizine (4-Az) en tant qu'inhibiteur GGPPS d'enzyme branchante clée dans la voie du mévalonate, en particulier dans la préparation d'un médicament destiné à traiter la stéatose hépatique non alcoolique. Par une série d'expériences, la présente invention a montré que 4-Az pouvait provoquer une dégradation dépendante de la voie ubiquitination-protéasome de la protéine GGPPS, avait un effet inhibiteur sur l'expression de la protéine GGPPS et pouvait être utilisé en tant qu'inhibiteur de l'expression de la protéine GGPPS. Plus particulièrement, l'azido phlorizine selon l'invention peut réduire l'accumulation de lipides et la dégénérescence graisseuse dans le foie, et peut réduire les taux d'alanine aminotransférase et d'aspartate aminotransférase dans le sang, peut protéger activement la fonction hépatique et peut être utilisé dans la préparation d'un médicament destiné à traiter la stéatose hépatique non alcoolique.
PCT/CN2018/114329 2017-11-07 2018-11-07 Utilisation d'azido phlorizine dans la préparation d'un médicament destiné au traitement de la stéatose hépatique non alcoolique WO2019091397A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201711085577.7A CN108721308A (zh) 2017-11-07 2017-11-07 叠氮根皮苷素在制备治疗非酒精性脂肪肝药物中的用途
CN201711085577.7 2017-11-07

Publications (1)

Publication Number Publication Date
WO2019091397A1 true WO2019091397A1 (fr) 2019-05-16

Family

ID=63940218

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/114329 WO2019091397A1 (fr) 2017-11-07 2018-11-07 Utilisation d'azido phlorizine dans la préparation d'un médicament destiné au traitement de la stéatose hépatique non alcoolique

Country Status (2)

Country Link
CN (1) CN108721308A (fr)
WO (1) WO2019091397A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108721308A (zh) * 2017-11-07 2018-11-02 南京大学 叠氮根皮苷素在制备治疗非酒精性脂肪肝药物中的用途
CN112843009B (zh) * 2021-03-26 2022-08-05 广西壮族自治区林业科学研究院 一种制备根皮苷混合降糖制剂的方法
CN113509555B (zh) * 2021-07-19 2022-05-03 中国药科大学 Akt2抑制剂在制备非酒精性脂肪肝病治疗药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101683351A (zh) * 2008-09-24 2010-03-31 汪鋆植 根皮苷在制备保肝药物或保健食品中的用途
CN108721308A (zh) * 2017-11-07 2018-11-02 南京大学 叠氮根皮苷素在制备治疗非酒精性脂肪肝药物中的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101683351A (zh) * 2008-09-24 2010-03-31 汪鋆植 根皮苷在制备保肝药物或保健食品中的用途
CN108721308A (zh) * 2017-11-07 2018-11-02 南京大学 叠氮根皮苷素在制备治疗非酒精性脂肪肝药物中的用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKUS HOSANG, E.: "PHOTOAFFINITY LABELING AND IDENTIFICATION OF (A COMPO- NENT OF) THE SMALL-INTESTINAL Na+, D-GLUCOSE TRANSPORTER USING 4-AZIDOPHLO- RIZIN", FEBS LETTERS, vol. 130, no. 2, 31 August 1981 (1981-08-31), pages 244 - 248, XP025605642, DOI: 10.1016/0014-5793(81)81130-1 *

Also Published As

Publication number Publication date
CN108721308A (zh) 2018-11-02

Similar Documents

Publication Publication Date Title
Wang et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis
Chen et al. Nrf2 at the heart of oxidative stress and cardiac protection
Saha et al. Extracellular vesicles from mice with alcoholic liver disease carry a distinct protein cargo and induce macrophage activation through heat shock protein 90
Wu et al. Hepatic exosome-derived miR-130a-3p attenuates glucose intolerance via suppressing PHLPP2 gene in adipocyte
Zhao et al. MiR‐30c protects diabetic nephropathy by suppressing epithelial‐to‐mesenchymal transition in db/db mice
Tang et al. Swimming prevents nonalcoholic fatty liver disease by reducing migration inhibitory factor through Akt suppression and autophagy activation
Li et al. Adenosine monophosphate-activated protein kinase induces cholesterol efflux from macrophage-derived foam cells and alleviates atherosclerosis in apolipoprotein E-deficient mice
Kong et al. Berberine reduces insulin resistance through protein kinase C–dependent up-regulation of insulin receptor expression
Xu et al. An Endoplasmic Reticulum Stress–Micro RNA‐26a Feedback Circuit in NAFLD
Baeza-Raja et al. p38 MAPK-induced nuclear factor-κB activity is required for skeletal muscle differentiation: role of interleukin-6
Gupta et al. An assessment of the role of reactive oxygen species and redox signaling in norepinephrine-induced apoptosis and hypertrophy of H9c2 cardiac myoblasts
Tang et al. Novel role of AMP-activated protein kinase signaling in cigarette smoke induction of IL-8 in human lung epithelial cells and lung inflammation in mice
Lei et al. Alpha-lipoic acid attenuates endoplasmic reticulum stress-induced insulin resistance by improving mitochondrial function in HepG2 cells
WO2019091397A1 (fr) Utilisation d'azido phlorizine dans la préparation d'un médicament destiné au traitement de la stéatose hépatique non alcoolique
Zhang et al. Targeting of miR-96-5p by catalpol ameliorates oxidative stress and hepatic steatosis in LDLr-/-mice via p66shc/cytochrome C cascade
Lu et al. MicroRNA-21-regulated activation of the Akt pathway participates in the protective effects of H2S against liver Ischemia–reperfusion injury
Siculella et al. Lipid accumulation stimulates the cap-independent translation of SREBP-1a mRNA by promoting hnRNP A1 binding to its 5′-UTR in a cellular model of hepatic steatosis
Park et al. Metformin-induced TTP mediates communication between Kupffer cells and hepatocytes to alleviate hepatic steatosis by regulating lipophagy and necroptosis
Yan et al. LncRNA SNHG1 exerts a protective role in cardiomyocytes hypertrophy via targeting miR‐15a‐5p/HMGA1 axis
Pérez-García et al. High-fat diet alters PAS kinase regulation by fasting and feeding in liver
Lv et al. Alpha lipoic acid modulated high glucose‐induced rat mesangial cell dysfunction via mTOR/p70S6K/4E‐BP1 pathway
Qian et al. Exacerbation of diabetic cardiac hypertrophy in OVE26 mice by angiotensin II is associated with JNK/c-Jun/miR-221-mediated autophagy inhibition
Yan et al. The antimicrobial peptide YD attenuates inflammation via miR-155 targeting CASP12 during liver fibrosis
Niu et al. Exendin-4 regulates redox homeostasis in rats fed with high-fat diet
Shen et al. SGLT2 inhibitor empagliflozin downregulates miRNA-34a-5p and targets GREM2 to inactivate hepatic stellate cells and ameliorate non-alcoholic fatty liver disease-associated fibrosis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18875514

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18875514

Country of ref document: EP

Kind code of ref document: A1